Differential CYP 2D6 metabolism alters primaquine pharmacokinetics

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 4, 2015, Pages 2380-2387

  Potter, Brittney M J ^a   Xie, Lisa H ^a   Vuong, Chau ^a   Zhang, Jing ^a   Zhang, Ping ^a   Duan, Dehui ^a   Luong, Thu Lan T ^a   Herath, H M T Bandara ^b   Nanayakkara, N P Dhammika ^b   Tekwani, Babu L ^b,c   Walker, Larry A ^b,c   Nolan, Christina K ^a   Sciotti, Richard J ^a   Zottig, Victor E ^a   Smith, Philip L ^a   Paris, Robert M ^a   Read, Lisa T ^a   Li, Qigui ^a   Pybus, Brandon S ^a   Sousa, Jason C ^a   Reichard, Gregory A ^a   Marcsisin, Sean R ^a   more..

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; PRIMAQUINE; ANTIMALARIAL AGENT;

AREA UNDER THE CURVE; AREA UNDER THE MOMENT CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HYDROXYLATION; KNOCKOUT MOUSE; LIQUID CHROMATOGRAPHY; LIVER; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; WILD TYPE; ANIMAL; BIOTRANSFORMATION; C57BL MOUSE; GENETICS; HALF LIFE TIME; METABOLISM;

ANIMALS; ANTIMALARIALS; AREA UNDER CURVE; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2D6; HALF-LIFE; HUMANS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PRIMAQUINE;

EID: 84928902226     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00015-15     Document Type: Article

References (28)

1. Coatney GR, Alving AS, Jones R, Jr, Hankey DD, Robinson DH, Garrison PL, Coker WG, Donovan WN, Di Lorenzo A, Marx RL, Simmons IH. 1953. Korean vivax malaria. V. Cure of the infection by primaquine administered during long-term latency. Am J Trop Med Hyg 2:985-988.
2. Edgcomb JH, Arnold J, Yount EH, Jr, Alving AS, Eichelberger L, Jeffery GM, Eyles D, Young MD. 1950. Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report. J Natl Malar Soc 9:285-292.
3. Fernando D, Rodrigo C, Rajapakse S. 2011. Primaquine in vivax malaria: an update and review on management issues. Malar J 10:351. http://dx.doi.org/10.1186/1475-2875-10-351.
4. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, Arthur P, Chuenchom N, Mohrle JJ, Duparc S, Ugwuegbulam C, Kleim JP, Carter N, Green JA, Kellam L. 2014. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet 383:1049-1058. http://dx.doi.org/10.1016/S0140-6736(13)62568-4.
5. Price RN, Nosten F. 2014. Single-dose radical cure of Plasmodium vivax: astepcloser. Lancet383:1020-1021.http://dx.doi.org/10.1016/S0140-6736 (13)62672-0.
6. Chotivanich K, Sattabongkot J, Udomsangpetch R, Looareesuwan S, Day NP, Coleman RE, White NJ. 2006. Transmission-blocking activities of quinine, primaquine, and artesunate. Antimicrob Agents Chemother 50:1927-1930. http://dx.doi.org/10.1128/AAC.01472-05.
7. Eziefula AC, Gosling R, Hwang J, Hsiang MS, Bousema T, von Seidlein L, Drakeley C, Primaquine in Africa Discussion Group. 2012. Rationale for short course primaquine in Africa to interrupt malaria transmission. Malar J 11:360. http://dx.doi.org/10.1186/1475-2875-11-360.
8. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, Deye G, Melendez V, Ockenhouse CF. 2013. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med 369: 1381-1382. http://dx.doi.org/10.1056/NEJMc1301936.
9. Jin X, Pybus BS, Marcsisin SR, Logan T, Luong TL, Sousa J, Matlock N, Collazo V, Asher C, Carroll D, Olmeda R, Walker LA, Kozar MP, Melendez V. 25 June 2013, posting date. An LC-MS based study of the metabolic profile of primaquine, an 8-aminoquinoline antiparasitic drug, with an in vitro primary human hepatocyte culture model. Eur J Drug Metab Pharmacokinet http://dx.doi.org/10.1007/s13318-013-0139-8.
10. Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, Caridha D, Zeng Q, Reichard GA, Ockenhouse C, Bennett J, Walker LA, Ohrt C, Melendez V. 2013. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar J 12:212. http://dx.doi.org/10.1186/1475-2875-12-212.
11. Pybus BS, Sousa JC, Jin X, Ferguson JA, Christian RE, Barnhart R, Vuong C, Sciotti RJ, Reichard GA, Kozar MP, Walker LA, Ohrt C, Melendez V. 2012. CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine. Malar J 11:259. http://dx.doi.org/10.1186/1475-2875-11-259.
12. Bernard S, Neville KA, Nguyen AT, Flockhart DA. 2006. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist 11:126-135. http://dx.doi.org/10.1634/theoncologist.11-2-126.
13. Bogni A, Monshouwer M, Moscone A, Hidestrand M, Ingelman-Sundberg M, Hartung T, Coecke S. 2005. Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles. Toxicol In Vitro 19:621-629. http://dx.doi.org/10.1016/j.tiv.2005.04.001.
14. Ingelman-Sundberg M. 2005. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6-13. http://dx.doi.org/10.1038/sj.tpj.6500285.
15. Zhou SF. 2009. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet 48:689-723. http://dx.doi.org/10.2165/11318030-000000000-00000.
16. Vásquez-Vivar J, Augusto O. 1992. Hydroxylated metabolites of the antimalarial drug primaquine. Oxidation and redox cycling. J Biol Chem 267:6848-6854.
17. Vásquez-Vivar J, Augusto O. 1994. Oxidative activity of primaquine metabolites on rat erythrocytes in vitro and in vivo. Biochem Pharmacol 47:309-316. http://dx.doi.org/10.1016/0006-2952(94)90022-1.
18. Avula B, Tekwani BL, Chaurasiya ND, Nanayakkara NP, Wang YH, Khan SI, Adelli VR, Sahu R, Elsohly MA, McChesney JD, Khan IA, Walker LA. 2013. Profiling primaquine metabolites in primary human hepatocytes using UHPLC-QTOF-MS with 13C stable isotope labeling. J Mass Spectrom 48:276-285. http://dx.doi.org/10.1002/jms.3122.
19. Mihaly GW, Ward SA, Edwards G, Orme ML, Breckenridge AM. 1984. Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. Br J Clin Pharmacol 17:441-446. http://dx.doi.org/10.1111/j.1365-2125.1984.tb02369.x.
20. Fasinu PS, Tekwani BL, Nanayakkara ND, Avula B, Herath HB, Wang YH, Adelli VR, Elsohly MA, Khan SI, Khan IA, Pybus BS, Marcsisin SR, Reichard GA, McChesney JD, Walker LA. 2014. Enantioselective metabolism of primaquine by human CYP2D6. Malar J 13:507. http://dx.doi.org/10.1186/1475-2875-13-507.
21. Vasquez-Vivar J, Augusto O. 1990. ESR detection of free radical inter-mediates during autoxidation of 5-hydroxyprimaquine. Free Radic Res Commun 9:383-389. http://dx.doi.org/10.3109/10715769009145698.
22. Bowman ZS, Oatis JE, Jr, Whelan JL, Jollow DJ, McMillan DC. 2004. Primaquine-induced hemolytic anemia: susceptibility of normal versus glutathione-depleted rat erythrocytes to 5-hydroxyprimaquine. J Pharmacol Exp Ther 309:79-85. http://dx.doi.org/10.1124/jpet.103.062984.
23. Yu AM, Haining RL. 2006. Expression, purification, and characterization of mouse CYP2d22. Drug Metab Dispos 34:1167-1174. http://dx.doi.org/10.1124/dmd.105.008870.
24. Scheer N, Kapelyukh Y, McEwan J, Beuger V, Stanley LA, Rode A, Wolf CR. 2012. Modeling human cytochrome P450 2D6 metabolism and drug-drug interaction by a novel panel of knockout and humanized mouse lines. Mol Pharmacol 81:63-72. http://dx.doi.org/10.1124/mol.111.075192.
25. Brossi A, Gessner W, Hufford CD, Baker JK, Homo F, Millet P, Landau I. 1987. Photooxidation products of primaquine. Structure, antimalarial activity and hemolytic effects. FEBS Lett 223:77-81.
26. Marcsisin SR, Sousa JC, Reichard GA, Caridha D, Zeng Q, Roncal N, McNulty R, Careagabarja J, Sciotti RJ, Bennett JW, Zottig VE, Deye G, Li Q, Read L, Hickman M, Dhammika Nanayakkara NP, Walker LA, Smith B, Melendez V, Pybus BS. 2014. Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds. Malar J 13:2. http://dx.doi.org/10.1186/1475-2875-13-2.
27. Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, Winzeler EA, Sinden RE, Leroy D. 2012. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med 9:e1001169. http://dx.doi.org/10.1371/journal.pmed.1001169.
28. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.